LQD (Lithium vs. Quetiapine in Depression) | C4C

The aim of the study is to determine whether it is more clinically and cost-effective to augment an antidepressant with lithium or quetiapine for patients with treatment resistant depression (TRD). A recent study by Bauer et al. in 2013 found that antidepressant augmentation with quetiapine XR was non-inferior to lithium in the management of patients with TRD over 6 weeks. However, it is important to study the long-term clinical and cost effectiveness of these two licenced and NICE recommended medications for TRD, especially due to high rates of relapse and the often chronic nature of TRD. Hence, we have designed the study to follow up the patients over 12 months.